Medication 'Pegasys'. Instructions. Description

Medication "Pegasys" is an immunomodulating drug with antiviral activity. The active substance is peginterferon alfa-2a.

Medication "Pegasys" instruction recommends for chronic hepatitis C in adults with positive RNA virus with compensated cirrhosis or without cirrhosis, including co-infection with HIV (clinically stable). In this case, the drug can be used alone or in a complex.

In combination with the medicine "Ribavirin", the "Pegasys" medication recommends that patients who have not received previous treatment, or if there is no effectiveness from previous monotherapy with unpigilated or pegylated interferon alfa, should be recommended.

The medication is prescribed for adults with chronic hepatitis B (HBeAg positive and negative) with compensated hepatic damage and viral replication symptoms, histologically confirmed fibrosis (or inflammation in the liver) and elevated ALT.

The use of the Pegasys medication is recommended for use under the supervision of a physician who has experience in the management of chronic hepatitis C and B.

In case of complex therapy, the medicine "Ribavirin" is applied in accordance with the annotation to it.

The medicine "Pegasys" instruction allows to enter only in the region of the thigh or the anterior wall of the peritoneum once a week. Injections are administered subcutaneously.

Before administration, it is necessary to examine the drug. The solution should not contain foreign impurities. The drug should not change color. The doctor should instruct the patient about the proper storage of the medication. The used materials must be disposed of. Do not re-use needles and syringes.

With HBeAg-negative and HBeAg-positive hepatitis In the chronic course, the drug "Pegasys 180" is prescribed every seven days. The duration of monotherapy is forty-eight weeks, taking into account the genotype.

In chronic hepatitis C, for patients who have not received previous treatment, the drug is also administered once a week. The recommended dose is 180 mcg in monotherapy or in combination with Ribavirin.

The drug is contraindicated in autoimmune hepatitis, decompensated cirrhosis, severe liver failure, hyperthyroidism, hypothyroidism, decompensated stage of diabetes mellitus. The medicine "Pegasys" is not prescribed for severe cardiovascular pathologies in the stage of decompensation, including under poorly controlled, unstable flow during the previous six months. Contraindicated drug for children under three years, with hypersensitivity to alpha interferons, as well as the products of vital activity of E. coli, polyethylene glycol or any other ingredients of the drug.

When using complex therapy with the drug "Ribavirin" should also take into account and contraindications to it.

With hepatitis C, the use of Pegasys during pregnancy is not allowed. If necessary, to use the remedy for lactating women, the question of stopping lactation should be resolved .

With caution appoint for cardiovascular and autoimmune pathologies, depression (in history including), psoriasis.

As a rule, the remedy "Pegasys" is transferred well. However, in some cases, individual adverse reactions are possible. Usually, after lowering the dose to 135 μg, undesirable effects are eliminated.

About the medicine "Pegasys" the opinions of specialists are generally positive. Many doctors indicate the effectiveness of the drug and the stability of the result achieved. In addition, the medication is well tolerated by patients. Very rarely on the background of treatment, there were side manifestations, which are mainly associated with hypersensitivity.

Treatment with Pegasys should only be carried out under the supervision of a doctor.